Wells Fargo & Company Surface Oncology, Inc. Transaction History

Wells Fargo & Company

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 15, 2023	BUY	$0.57 - $0.88 $9 - $14	16 Added 1.85%	880 $0
Q1 2023 May 12, 2023	BUY	$0.61 - $1.03 $64 - $108	105 Added 13.83%	864 $0
Q4 2022 Feb 13, 2023	BUY	$0.62 - $1.21 $14 - $29	24 Added 3.27%	759 $0
Q3 2022 Nov 14, 2022	BUY	$1.05 - $2.1 $64 - $128	61 Added 9.05%	735 $0
Q2 2022 Aug 12, 2022	SELL	$1.42 - $3.15 $184,672 - $409,660	-130,051 Reduced 99.48%	674 $1,000
Q1 2022 May 16, 2022	SELL	$2.65 - $5.08 $17,601 - $33,741	-6,642 Reduced 4.84%	130,725 $384,000
Q4 2021 Feb 14, 2022	SELL	$4.73 - $7.9 $1.02 Million - $1.7 Million	-215,695 Reduced 61.09%	137,367 $656,000
Q3 2021 Nov 15, 2021	BUY	$5.16 - $7.98 $1.79 Million - $2.76 Million	346,235 Added 5071.55%	353,062 $2.67 Million
Q2 2021 Aug 16, 2021	SELL	$6.45 - $9.09 $161,346 - $227,386	-25,015 Reduced 78.56%	6,827 $51,000
Q1 2021 May 13, 2021	SELL	$7.25 - $13.82 $19,843 - $37,825	-2,737 Reduced 7.92%	31,842 $249,000
Q4 2020 Feb 09, 2021	BUY	$6.87 - $10.48 $236,664 - $361,025	34,449 Added 26499.23%	34,579 $318,000
Q3 2020 Nov 05, 2020	BUY	$5.06 - $7.23 $333 - $477	66 Added 103.13%	130 $1,000
Q2 2020 Aug 13, 2020	BUY	$1.57 - $6.56 $1 - $6	1 Added 1.59%	64 $0
Q1 2020 May 14, 2020	BUY	$1.44 - $3.95 $90 - $248	63 New	63 $0

315K

Ticker SURF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,034,000
Description
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibo...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.